Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$110.94 USD

110.94
7,458,602

+1.05 (0.96%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (99 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Here's Why AbbVie Stock is Good for Your Portfolio's Health

Here are six reasons why investing in AbbVie (ABBV) stock is a good decision now.

    The Zacks Analyst Blog Highlights: Facebook, Amgen, Abbott, Coca-Cola and 3M

    The Zacks Analyst Blog Highlights: Facebook, Amgen, Abbott, Coca-Cola and 3M

      Mark Vickery headshot

      Top Stock Reports for Facebook, Amgen & Abbott

      Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Amgen (AMGN), and Abbott (ABT).

        Sweta Jaiswal headshot

        Tap Cardiovascular Devices Market Boom With These 3 Stocks

        Consider these three stocks in the rapidly-growing cardiovascular devices market.

          Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical

          Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical

            Boston Scientific Up on Possible Takeover Bid by Stryker

            Even if Boston Scientific's (BSX) position remains indefinite on a possible sell-off rumor, the company's strategic stance on this might however, swing in its favor for winning a competitive marketing edge.

              Bio-Rad Banks on Solid Global Scenario, Competition Rife

              Bio-Rad (BIO) delivers robust performance, primarily in North America, China and the Asia-Pacific region.

                Abbott Launches Afinion 2 Analyzer Rapid Test in the U.S.

                Abbott's (ABT) recently-launched Afinion 2 analyzer system is likely to boost top-line contributions from the Diagnostic division.

                  The Zacks Analyst Blog Highlights: Duke, Charter Communications, Abbott, UnitedHealth and Brown-Forman

                  The Zacks Analyst Blog Highlights: Duke, Charter Communications, Abbott, UnitedHealth and Brown-Forman

                    Abbott Presents Positive Data for AMPLATZER Amulet Device

                    Abbott (ABT) proceeds with initiatives to boost the core Structural Heart division.

                      Abbott Presents Positive Study Results for Tendyne Device

                      Abbott (ABT) leaves no stone unturned to drive its Structural Heart business.

                        Abbott Gets FDA Nod for XIENCE Sierra, To Boost Vascular Wing

                        Abbott (ABT) continues with the slew of developments in regards with the XIENCE Sierra coronary stent system.

                          Cardiovascular Systems Rides on New Products Amid Tight Race

                          Cardiovascular Systems (CSII) gains traction from a strong third-quarter fiscal 2018, witnessing a year-over-year revenue rise at both CAD and PAD businesses.

                            Why Is Abbott (ABT) Up 2% Since Its Last Earnings Report?

                            Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                              Merck vs. Pfizer: Which Stock Looks Better Post Q1 Earnings?

                              Both Merck and Pfizer reported upbeat first-quarter results on May 1

                                Universal Health (UHS) Q1 Earnings & Revenues Lag Estimates

                                Universal Health (UHS) posts a solid Q1 driven by higher revenues.

                                  Anthem (ANTM) Beats on Q1 Earnings, Raises '18 Guidance

                                  Strong performance across segments supports Anthem's (ANTM) first-quarter results.

                                    Centene (CNC) Q1 Earnings & Revenues Top, '18 View Lowered

                                    Centene (CNC) delivers strong first-quarter results on the back of significant membership growth.

                                      The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive

                                      The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive

                                        Abbott (ABT) Q1 Earnings & Revenues Top, '18 View Retained

                                        Abbott (ABT) continues to gain from a strong and consistent EPD as well as a robust Medical Devices performance.

                                          MS, USB, ABT & TXT Leads Q1 Earnings

                                          MS, USB, ABT & TXT Leads Q1 Earnings

                                            Mark Vickery headshot

                                            Q1 Earnings Keep Markets in the Green: MS, USB, ABT & TXT

                                            We are still in the early stages so far, but overall results have been notably better than expected.

                                              Abbott (ABT) Beats on Earnings and Revenues in Q1

                                              Abbott (ABT) gains ground on new product launches and delivers strong Q1 results.

                                                Tracey Ryniec headshot

                                                5 Amazing Earnings Charts This Week

                                                It's not easy to beat the estimate nearly every quarter for years. But these 5 companies are doing it.

                                                  Varian Medical (VAR) Q2 Earnings: Is a Surprise in Store?

                                                  Strong revenue opportunity from various Oncology and Imaging Component products is likely to drive Varian Medical (VAR) in Q2.